FDA lifts clinical hold on anthrax vaccine

The FDA has lifted the clinical hold on PharmAthene's ($PIP) anthrax vaccine candidate, SparVax. A Phase II trial was put on hold in August before enrolling a patient, but it can now begin after PharmAthene gave FDA more stability data. SparVax is a rival to Emergent BioSolutions' current and pipeline vaccines. Release | More